乳腺癌是一个世界范围内的严重危害妇女健康的恶性肿瘤,在我国其发病率不断上升。但乳腺癌总体治愈率近10年来没有得到显著提高。目前临床治疗效果略有改观的主要原因是由于早期发现、早期诊断、早期治疗,而不是治疗方法本身进步。治疗...乳腺癌是一个世界范围内的严重危害妇女健康的恶性肿瘤,在我国其发病率不断上升。但乳腺癌总体治愈率近10年来没有得到显著提高。目前临床治疗效果略有改观的主要原因是由于早期发现、早期诊断、早期治疗,而不是治疗方法本身进步。治疗失败的主要原因是肿瘤的复发和转移。肿瘤的生长、侵袭和转移依赖于血管和淋巴管的生成。对乳腺癌等上皮组织起源的肿瘤而言,淋巴道播散是首要的转移途径。乳腺癌肿瘤存在高微血管密度和高微淋巴管密度,抑制肿瘤的微血管和微淋巴管生成即可抑制肿瘤的生长、侵袭、复发和转移。人们较早发现微血管标记物,乳腺癌的抗血管生成治疗研究较早,现已经有30多种抗血管生成药物,内皮抑素是目前最强的血管生成抑制因子;最近人类才发现podop lan in等淋巴管特异性标记物,因而对乳腺癌的抗淋巴管生成治疗研究还处于起步阶段。可以预测,在不久的将来,以抗肿瘤血管和淋巴管生成治疗为主的生物治疗方法将为乳腺癌的综合治疗带来一次新的飞跃。展开更多
Objective： This study aims to investigate the clinicopathologic significance of lymphatic vessel invasion （LVI） labeled by D2-40 monoclonal antibody in esophageal squamous cell carcinoma （ESCC）. Methods： Immunoh...Objective： This study aims to investigate the clinicopathologic significance of lymphatic vessel invasion （LVI） labeled by D2-40 monoclonal antibody in esophageal squamous cell carcinoma （ESCC）. Methods： Immunohistochemical assay was used to detect the expression of D2-40 and LVI in 107 ESCC patients. Then, the correlation between the clinicopathologic feature and the overall survival time of the patients was analyzed. Results： The lymph node metastasis rates were 70% and 21% in the LVI-positive and LVI-negative groups, respectively. The nodal metastasis rate was higher in the LVI-positive group than in the LVI-negative group. Multivariate regression analysis showed that LVI was related to nodal metastasis （P〈0.001）. The median survival time of the patients was 26 and 43 months in the LVI-positive and LVI-negative groups, respectively. Mthough univariate regression analysis showed significant difference between the two groups （P=0.014）, multivariate regression analysis revealed that LVI was not an independent prognostic factor for overall survival in the ESCC patients （P=0.062）. Lymphatic node metastasis （P=0.031）, clinical stage （P=0.019）, and residual tumor （P=0.026） were the independent prognostic factors. Conclusion： LVI labeled by D2-40 monoclonal antibody is a risk factor predictive of lymph node metastasis in ESCC patients.展开更多
文摘乳腺癌是一个世界范围内的严重危害妇女健康的恶性肿瘤,在我国其发病率不断上升。但乳腺癌总体治愈率近10年来没有得到显著提高。目前临床治疗效果略有改观的主要原因是由于早期发现、早期诊断、早期治疗,而不是治疗方法本身进步。治疗失败的主要原因是肿瘤的复发和转移。肿瘤的生长、侵袭和转移依赖于血管和淋巴管的生成。对乳腺癌等上皮组织起源的肿瘤而言,淋巴道播散是首要的转移途径。乳腺癌肿瘤存在高微血管密度和高微淋巴管密度,抑制肿瘤的微血管和微淋巴管生成即可抑制肿瘤的生长、侵袭、复发和转移。人们较早发现微血管标记物,乳腺癌的抗血管生成治疗研究较早,现已经有30多种抗血管生成药物,内皮抑素是目前最强的血管生成抑制因子;最近人类才发现podop lan in等淋巴管特异性标记物,因而对乳腺癌的抗淋巴管生成治疗研究还处于起步阶段。可以预测,在不久的将来,以抗肿瘤血管和淋巴管生成治疗为主的生物治疗方法将为乳腺癌的综合治疗带来一次新的飞跃。
基金supported by the Science and Technology Development Planning of Shandong Provincethe China Postdoctoral Science Fund (Grant No.2012GGE27088 andNo.2011M500531)
文摘Objective： This study aims to investigate the clinicopathologic significance of lymphatic vessel invasion （LVI） labeled by D2-40 monoclonal antibody in esophageal squamous cell carcinoma （ESCC）. Methods： Immunohistochemical assay was used to detect the expression of D2-40 and LVI in 107 ESCC patients. Then, the correlation between the clinicopathologic feature and the overall survival time of the patients was analyzed. Results： The lymph node metastasis rates were 70% and 21% in the LVI-positive and LVI-negative groups, respectively. The nodal metastasis rate was higher in the LVI-positive group than in the LVI-negative group. Multivariate regression analysis showed that LVI was related to nodal metastasis （P〈0.001）. The median survival time of the patients was 26 and 43 months in the LVI-positive and LVI-negative groups, respectively. Mthough univariate regression analysis showed significant difference between the two groups （P=0.014）, multivariate regression analysis revealed that LVI was not an independent prognostic factor for overall survival in the ESCC patients （P=0.062）. Lymphatic node metastasis （P=0.031）, clinical stage （P=0.019）, and residual tumor （P=0.026） were the independent prognostic factors. Conclusion： LVI labeled by D2-40 monoclonal antibody is a risk factor predictive of lymph node metastasis in ESCC patients.
